At the news
? BULLISHIMPACT 5/10 8-K filed May 18, 2026 at 17:20 ET
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of BCG, securing a second potential source of BCG for bladder cancer treatment. The agreement provides exclusive U.S. rights with no upfront payment, and ImmunityBio will lead regulatory submissions and commercialization. Positive Phase III data from the SWOG S1602 trial supports non-inferiority versus TICE BCG, but the product remains investigational in the U.S.
- Exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG.
- No upfront or milestone payments; all vials for regulatory submission provided at no cost.
- ImmunityBio is sole BLA applicant and marketing authorization holder; 10-year term from FDA approval.
- SWOG S1602 Phase III trial demonstrated non-inferiority of Tokyo-172 BCG vs TICE BCG (HR 0.82, 95.8% CI 0.63-1.08).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access